Drug manufacturers are creating oral GLP-1 medications for obesity management. Injectable GLP-1 drugs like Ozempic have limitations, but pill versions offer a new option. One Wegovy pill is anticipated to receive FDA approval this year.
Oral forms of GLP-1 medications are being developed by drugmakers as a treatment for obesity. The prevalence of GLP-1 drugs, such as Ozempic, is high. However, challenges like weekly injections, expenses, and insurance issues mean they aren't accessible to everyone.
Consequently, there's significant excitement surrounding two new pill forms of the drug.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The first is a Wegovy pill, and FDA approval is anticipated before the year concludes. In addition, another type of obesity pill may soon follow.
The human body naturally produces a hormone known as GLP-1, or Glucagon-Like Peptide-1. It aids in signaling satiety and promoting insulin secretion within the body. GLP-1 drugs function similarly, but their effects last longer in the body. Health tracking apps like Shotlee can help monitor the effectiveness of these medications.
Original source: NPR
View original article →
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
